{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-002739","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.583980+00:00","generated_at":"2026-05-22T21:42:53.874356+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioCryst Q1 ORLADEYO revenue $134.2M (+51% YoY); raises FY guidance to $580-600M; expects FY 2025 profitability","bullets":["Q1 ORLADEYO net rev $134.2M (+51% YoY); total rev $145.5M (+56.8% YoY); net income $32K vs loss $35.4M.","FY 2025 ORLADEYO rev guidance raised to $580-600M (from $535-550M); company expects net income and positive cash flow for full year.","Paid down $75M of Pharmakon debt in April; expects ~$23.5M interest savings over life of loan.","NDA submitted for ORLADEYO oral granules for HAE children aged 2-11; IND cleared for BCX17725 for Netherton syndrome.","% paid ORLADEYO patients increased to ~84% (from 73.5% end 2024); U.S. preference for oral prophylaxis rose to 70%."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-002739","json":"https://secwatch.observer/filing/0001171843-25-002739.json","markdown":"https://secwatch.observer/filing/0001171843-25-002739.md","text":"https://secwatch.observer/filing/0001171843-25-002739.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184325002739/0001171843-25-002739-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184325002739/f8k_050525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T21:42:53.874356+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}